PTC Therapeutics Swings to Q3 Loss, Revenue Rises; Increases 2026 Outlook

04:48 PM EDT, 10/29/2026 (MT Newswires) -- PTC Therapeutics (PTCT) reported a Q3 net loss late Thursday of $0.62 per diluted share, swinging from a profit of $0.20 a year earlier. Four analysts polled by FactSet expected $0.14. Total revenue for the quarter ended Sept 30 rose to $357.8 million from $211 million a year earlier. Analysts expected $306.4 million. For 2026, the company now expects total revenue of $1.29 to $1.32 billion, up from its prior guidance of $1.18 billion to $1.28 billion. Analysts expect $1.26 billion.